Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline

March 11, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search